Skip to content
OpenCapital
Get started

Quince Therapeutics, Inc. QNCX Q3 2025 earnings

Reported November 12, 2025 · Before market open

Diluted EPS-$0.25Miss by $0.05
EPS estimate-$0.20

Next report

Aug 11, 2026 (in a month)
EPS estimate-$25.40

Versus estimates

Diluted EPS

Q1 2026-$0.59Beat by $0.71
Q3 2025-$0.25Miss by $0.05
Q2 2025-$0.34Miss by $0.06Q1 2025-$0.34Miss by $0.10Q4 2024-$0.28Miss by $0.09Q3 2024-$0.13Beat by $0.04

Ask the moment Quince Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Quince Therapeutics, Inc. report Q3 2025 earnings?
Quince Therapeutics, Inc. (QNCX) reported Q3 2025 earnings on November 12, 2025 before market open.
What were Quince Therapeutics, Inc.'s Q3 2025 revenue and EPS?
Quince Therapeutics, Inc. reported diluted EPS of $-0.25 for Q3 2025.
Did Quince Therapeutics, Inc. beat estimates in Q3 2025?
EPS missed the consensus estimate of $-0.20 by $0.05.
How did Quince Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS declined 92.3% from $-0.13.
Where can I find Quince Therapeutics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-277523) and the 10-Q periodic report (0001193125-25-277529) directly on SEC EDGAR. The filing index links above go to sec.gov.